Skip to main content

Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update

Cardiol Therapeutics Inc

2265 Upper Middle Road East
Suite 602
Oakville ON L6H 0G5 CAN
P: 289-910-0850
https://www.cardiolrx.com

Sectors & Indices

Sector
Industry
Employees

Profile

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Key Executives

NameTitle
Christopher J. WaddickCFO/Director/Secretary
David G. ElsleyCEO/Director/President
Andrew HamerChief Medical Officer
Bernard LimCOO

More from The Globe